Metsera (NASDAQ:MTSR) Stock Price Down 9.7% - What's Next?

Key Points

• Metsera Inc. (NASDAQ:MTSR) shares dropped 9.7% to close at $35.61, significantly below the previous day's close of $39.43, with a trading volume decline of 76% from average levels.
• Analyst opinions are generally positive, with Guggenheim raising its price target from $56.00 to $62.00, while Wells Fargo initiated coverage with an "overweight" rating and a $65.00 target, contributing to a consensus price target of $55.00.
• Metsera is engaged in developing innovative hormone therapies for treating obesity, with its product pipeline including several peptide analogs, indicating a focus on addressing significant health issues.

Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s share price dropped 9.7% on Tuesday . The stock traded as low as $34.07 and last traded at $35.61. Approximately 216,353 shares changed hands during trading, a decline of 76% from the average daily volume of 902,209 shares. The stock had previously closed at $39.43.

Wall Street Analysts Forecast Growth

MTSR has been the subject of several recent research reports. Guggenheim raised their price target on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Wells Fargo & Company initiated coverage on Metsera in a report on Friday, June 20th. They set an "overweight" rating and a $65.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Metsera currently has a consensus rating of "Buy" and a consensus target price of $55.00.

Metsera Stock Up 5.8%

The company has a fifty day simple moving average of $32.59.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MTSR. Alphabet Inc. acquired a new position in Metsera in the first quarter valued at $135,059,000. T. Rowe Price Investment Management Inc. acquired a new position in Metsera in the first quarter valued at $78,748,000. Wellington Management Group LLP acquired a new position in Metsera in the first quarter valued at $65,382,000. Alpha Wave Global LP acquired a new position in shares of Metsera during the first quarter worth about $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of Metsera during the first quarter worth about $42,395,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.